{
    "nctId": "NCT06009627",
    "briefTitle": "Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients",
    "officialTitle": "Phase II Clinical Study of Darsilide Combined With Exemestane+Goserelin Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 119,
    "primaryOutcomeMeasure": "Objective response rate (ORR) for treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* All patients were operable estrogen receptor (ER) positive (\\>1%), regardless of PR expression level, HER2 receptor negative invasive breast cancer. Follow the 2018 ASCO-CAP HER2 negative interpretation guideline standard. Confirmed by the pathological laboratory that the immunohistochemical (IHC) score is 0 or 1-2+and the in situ hybridization (ISH) test is negative (ISH amplification rate\\<2.0);\n* Stage II-III initial treatment patients whose tumor staging meets the AJCC 8th edition standards;\n* At least one measurable breast and/or axillary disease;\n* ECOG 0-1, with an estimated lifespan of at least 12 months;\n* The functional level of the main organs must meet the following requirements:\n\nBlood routine: ANC \u2265 1.5 \u00d7 ten9/L; PLT \u2265 90 \u00d7 ten9/L; Hb \u2265 90 g/L;Blood biochemistry: TBIL \u2264 2.5 \u00d7 ULN; ALT and AST \u2264 2.5 \u00d7 ULN; BUN and Cr\u2264 1.5 \u00d7 ULN;\n\n* Lead ECG: QT interval (QTcF) corrected by Fridericia method\\<470 ms for women;\n* Able to accept all puncture biopsies required by the protocol;\n* Volunteer to join this study, sign informed consent, have good compliance, and be willing to cooperate with follow-up;\n* Women with fertility potential must have a negative Pregnancy test (urine or serum) within 7 days after administration,\n\nAnd agree to use acceptable birth control methods during the study period to avoid pregnancy.\n\nExclusion Criteria:\n\n* Received any form of anti-tumor treatment within 28 days prior to the start of the study;\n* Simultaneously receiving any anti-tumor treatment beyond the provisions of other protocols;\n* Bilateral breast cancer, inflammatory breast cancer or occult breast;\n* Stage IV breast cancer;\n* Severe dysfunction of important organs such as heart, liver, and kidney;\n* Unable to swallow, chronic diarrhea and Bowel obstruction, there are many factors that affect drug taking and absorption;\n* Participated in other drug clinical trials within 4 weeks prior to enrollment;\n* Those with a known history of allergies to the drug components of this protocol; Have a history of immunodeficiency, including positive Diagnosis of HIV/AIDS test Sex, HCV, active hepatitis B, or other acquired or congenital immunodeficiency diseases Illness or a history of organ transplantation;\n* Have ever suffered from any heart disease, including: (1) arrhythmia that requires medication or has clinical significance",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}